206A Stock Overview
A biotechnology company, discovers and develops small molecule inhibitors of protein-protein interaction targets utilizing proprietary PepMetics technology for treating patients suffering from cancer, autoimmune, fibrosis, and other diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
PRISM BioLab Co.,LTD Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥502.00 |
| 52 Week High | JP¥672.00 |
| 52 Week Low | JP¥440.00 |
| Beta | 0 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -11.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| 206A | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | 5.0% | -1.0% | -5.2% |
| 1Y | n/a | 15.8% | 15.7% |
Return vs Industry: Insufficient data to determine how 206A performed against the JP Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 206A performed against the JP Market.
Price Volatility
| 206A volatility | |
|---|---|
| 206A Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 4.0% |
| Market Average Movement | 3.7% |
| 10% most volatile stocks in JP Market | 7.3% |
| 10% least volatile stocks in JP Market | 1.8% |
Stable Share Price: 206A's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 206A's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | n/a | Dai Takehara | prismbiolab.com |
PRISM BioLab Co.,LTD, a biotechnology company, discovers and develops small molecule inhibitors of protein-protein interaction targets utilizing proprietary PepMetics technology for treating patients suffering from cancer, autoimmune, fibrosis, and other diseases. It develops E7386 targeting CBP/beta-catenin, which is in Phase II clinical trial for the treatment of cancer; and PRI724 targeting CBP/beta-catenin that is in Phase II clinical trial for treating cirrhosis. The company has license agreements with Eisai Co., Ltd.
PRISM BioLab Co.,LTD Fundamentals Summary
| 206A fundamental statistics | |
|---|---|
| Market cap | JP¥17.68b |
| Earnings (TTM) | JP¥0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs 206A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 206A income statement (TTM) | |
|---|---|
| Revenue | JP¥0 |
| Cost of Revenue | JP¥0 |
| Gross Profit | JP¥0 |
| Other Expenses | JP¥0 |
| Earnings | JP¥0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did 206A perform over the long term?
See historical performance and comparison